Reported research findings
- Evidence to date is preclinical and exploratory; no established human clinical trials define efficacy or safety in people.
HEALING & IMMUNE RESEARCH
KPV
A small three-amino-acid peptide studied for calming inflammation and protecting tissue, especially in the gut.
KPV is the active tail end of alpha-MSH, a natural signaling hormone—the fragment that carries its anti-inflammatory and tissue-protective effects without the skin-pigmentation effect of the full hormone. It is one of the most researched short peptides for inflammation and gut repair in preclinical and exploratory studies.
Why BLP features KPV
Included because it has a specific, well-defined anti-inflammatory mechanism (NF-κB and cytokine modulation) and a growing research following. Human clinical evidence remains preclinical and exploratory, so it is presented as experimental.
Mechanism
Strongly inhibits NF-κB, the master switch that turns on the inflammatory response.
Reduces the key inflammatory messengers (TNF-α, IL-1, IL-8) released by immune cells and by the cells lining the gut.
Supports the integrity of that lining and its healing, without broadly suppressing the immune system.
WHAT THE RESEARCH MEASURED
Research findings
Findings describe study outcomes, not expected personal results.
Preclinical findings
- In colitis/IBD models: significant reduction in inflammation and faster resolution.
- Reported accelerated mucosal and gut healing with restored barrier function.
- Reported calmer skin inflammation and enhanced wound repair.
- Naturally derived and very well tolerated in research use; rare mild injection-site reactions.
Regulatory status
KPV is investigational with primarily preclinical evidence. Sold and offered strictly for laboratory and research use.